A detailed history of Srs Capital Advisors, Inc. transactions in Biocryst Pharmaceuticals Inc stock. As of the latest transaction made, Srs Capital Advisors, Inc. holds 738 shares of BCRX stock, worth $5,660. This represents 0.0% of its overall portfolio holdings.

Number of Shares
738
Previous 778 5.14%
Holding current value
$5,660
Previous $4,000 25.0%
% of portfolio
0.0%
Previous 0.0%

Shares

6 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 06, 2024

SELL
$6.41 - $8.69 $256 - $347
-40 Reduced 5.14%
738 $5,000
Q2 2024

Aug 06, 2024

BUY
$4.13 - $6.79 $2,866 - $4,712
694 Added 826.19%
778 $4,000
Q1 2024

May 14, 2024

BUY
$4.89 - $7.65 $156 - $244
32 Added 61.54%
84 $0
Q2 2023

Aug 14, 2023

BUY
$6.96 - $8.81 $6 - $8
1 Added 1.96%
52 $0
Q1 2023

May 16, 2023

BUY
$7.94 - $11.84 $103 - $153
13 Added 34.21%
51 $0
Q4 2022

Feb 24, 2023

BUY
$10.5 - $14.2 $399 - $539
38 New
38 $0

Others Institutions Holding BCRX

About BIOCRYST PHARMACEUTICALS INC


  • Ticker BCRX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 185,944,992
  • Market Cap $1.43B
  • Description
  • BioCryst Pharmaceuticals, Inc., a biotechnology company, discovers novel, oral, and small-molecule medicines. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat...
More about BCRX
Track This Portfolio

Track Srs Capital Advisors, Inc. Portfolio

Follow Srs Capital Advisors, Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Srs Capital Advisors, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Srs Capital Advisors, Inc. with notifications on news.